Today Razib talks to Chris Bradley, a serial entrepreneur and the CEO and Co-Founder of Matter Bio, a company dedicated to preserving genome integrity and addressing the root causes of aging. With a multidisciplinary background spanning neuroscience, cell biology, and computer science, Bradley aims to translate early-stage biotech concepts into practical therapies that can extend human lifespan Matter Bio is focused on diagnosing, quantifying, and repairing the structural variations and mutations that accumulate in human DNA. Bradley has BS is neuroscience and cell biology from Rutgers and a MS in computer science from New York University.

The discussion first aims to focus on fundamental science concepts. What is genome integrity, and why does it matter? Bradley reviews the current state of the science to understand how errors creep into our genomic code over our lifetimes, and how it can lead to cancers and other pathologies. He points out that there is a wide variation in lifespan and cancer-risk across animal species, showing that in some ways nature may have "solved" the problem. In addition, Razib reiterates how complex and amazing any genome is, with billions of base pairs, and how incredible it is that our body's repair mechanisms function as well as they do.

Bradley then discusses the practical goals of Matter Bio as they begin their first clinical trials. Rather than just focusing on basic science, Bradley's long-term focus is to make a difference in human lives. He discusses how the drastic gain in human life expectancy over the last 150 years already shows that we can increase longevity. Ultimately, Matter Bio aims to push the frontier so that we are less and less surprised by centenarians. Bradley also addresses the reality that a lot of the innovation in biotech right now, including what Matter Bio wants to achieve, is limited by the regulatory state, rather than what can be done in terms of the science or funding environment.

Today, Razib talks to Chris Masterjohn, a nutritional scientist and leading expert in mitochondrial biology who believes hidden energy bottlenecks underlie much of modern disease. After years of work as a professor and researcher, he founded Mitome, the first mitochondrial analysis designed for everyday health, and serves as its Scientific Director. His mission is to make mitochondrial testing accessible so people can identify and correct the specific energy limitations holding them back. After earning his PhD in Nutritional Sciences from the University of Connecticut in 2012, he completed a postdoctoral research fellowship at the University of Illinois at Urbana-Champaign and subsequently served as an Assistant Professor of Health and Nutrition Sciences at Brooklyn College. He has a Substack.

Razib and Masterjohn first discuss the impact of social media on the communication of science, and his wrangling with the public health establishment during the COVID-19 pandemic. Masterjohn explains how digging into the primary literature showed that the authorities were claiming far greater certainty than they should have, and recounts attempts to censor and rebuke him when he pointed this out. He also addresses some misrepresentations that Anthony Fauci engaged in during his tenure. Next, Razib asks Masterjohn about the insights he has gained from nutritional science in terms of how he lives his own life, and his overall philosophy of public health. Masterjohn pushes against the tendency to over-medicalize and rely on pharmaceuticals before looking to common-sense nutrition and exercise. They then discuss the importance of the mitochondrion in molecular genetics, and how that is relevant both in terms of physiology and evolution. Masterjohn then talks about his company, Mitome, and the added value of greater and greater metabolic and genetic information in the present age.

On this episode of Unsupervised Learning, Razib talks to Mike White, a Genetics professor at the Washington University in St. Louis. White has a position at the School of Medicine in St. Louis, where he leads a research team focused on understanding the biophysical architecture of regulatory DNA. He earned a B.A. in music before pivoting to the sciences, receiving his Ph.D. in Biochemistry from the University of Rochester in 2006 and completing a postdoctoral fellowship at Wash U under Dr. Barak Cohen. White's work combines functional genomics, synthetic biology, computational biology, and deep learning to decipher how cells interpret regulatory sequences. His lab aims to predict how non-coding genetic variations impact complex human traits and disease risk, while exploring how to apply transcriptional circuits for broader applications in health and agriculture.

Razib first talks to White about the cultural, political and social winds moving through academia since 2010. How did academic science become so politically polarized, and what significance does it have for future funding streams? White brings his insights from the viewpoint of someone whose perch is in a medical school, and so somewhat at the margins of the cultural revolution sweeping through academia and even STEM. He notes it seems that the activist high tide peaked around 2020, though the hostility between the Right and institutional academia continues unabated, affecting NIH funding.

Then White discusses where we are in terms of understanding gene regulation, and its importance in biological function. Razib and White review how almost 99% of the human genome does not code for proteins, so often it is called "junk DNA," but the reality is that there are other functions in that region, first and foremost, regulating and modifying protein expressing regions. Razib asks White where we are in human genomics more than 25 years after the draft, has it lived up to expectations? And where we are going in the future?